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Objective. To determine the eﬀects of Tinospora crispa on serum glucose and insulin levels in healthy subjects and patients with
type 2 diabetes mellitus. Method. Serum from 10 healthy subjects and 10 diabetic participants, who had fasted overnight, were
obtained every 30–60 minutes during the 3 hours of continued fasting and during the 3 hours after ingestion of 75g of glucose
with or without ingestion of 125 or 250g of Tinospora crispa dry powder capsule. Glucose and Insulin levels were analyzed and
the areas under the curve for mean serum glucose and insulin levels were calculated. Result. The areas under the curve of mean
serum glucose and insulin levels in both healthy and diabetic participants were not signiﬁcantly diﬀerent between with or without
Tinospora crispa dry powder capsule. In diabetic participants the area under the curve of glucose was slightly lesser when 250mg of
Tinospora crispa was ingested, but not reaching statistical signiﬁcance (478 and 444mg min/ml, resp., P = 0.57). Conclusion.T h e
results suggest that Tinospora crispa ingestion cannot aﬀect serum glucose and insulin levels in healthy subjects or patients with
type 2 diabetes mellitus.
1.Introduction
Diabetes mellitus (DM), one of the major non-communica-
ble diseases, has become a major public health problem
and has increased prevalence in the modern world, even in
developing countries such as Thailand [1]. As with other
diseases,DMhasbeentreatedbyoraladministrationofplant
extracts based on traditional medicine since ancient times
[2]. Tinospora crispa (T. crispa, Menispermaceae), a medi-
cinal plant used to treat DM, was able to cause a reduction
in serum glucose level in diabetic rats, and the hypoglycemic
eﬀect was probably due to its insulinotropic activity [3]. T.
crispa also increased peripheral utilization of glucose and
inhibited hepatic glucose release [4].
Sangsuwan et al. [5] showed that T. crispa had no eﬃcacy
for therapy in patients with type 2 DM who did not respond
to an adequate dose of oral hypoglycemic drugs for at least 2
months and still had a glycosylated hemoglobin of greater
than 8.5%. There were no signiﬁcant changes in fasting
serum glucose or glycosylated hemoglobin between those
collected at baseline and during the study period in either
group. In this study the author suggests that T. crispa did
not stimulate insulin secretion in poor controlled diabetes
because these patients might not the have ability to secrete
insulin.Eﬃcacyof T. crispa shouldbeinvestigatedindiabetic
patient who responded to oral hypoglycemic drugs and did
not use insulin therapy because pancreas in these patients
might have ability of insulinotropic activity.
The objective of this study was to determine the eﬀects of
T. crispa on serum glucose and insulin levels in patients with
type 2 DM and healthy subjects.
2.MaterialandMethod
2.1. Subjects. After approval from the Ethics Committee for
Human Studies of Ramathibodi Hospital, Mahidol Univer-
sity, 10 participants (7 women and 3 men) with type 2 DM
between the ages of 32 and 64 years and 10 healthy partici-
pants (6 women and 4 men) with normal oral glucose toler-
ance test between the ages of 23 and 33 years were enrolled,
type 2 DM participants responded to oral hypoglycemic
drugs and discontinued oral hypoglycemic drugs at least 1
month. Patients with liver disease, heart disease, renal impai-
rment,orthosewhopreviouslyreceivedtraditionalmedicine2 Journal of Biomedicine and Biotechnology
Table 1: Baseline characteristics of the subjects in the study.
Characteristics Diabetic participants (n = 10) Healthy participants (n = 10)
Gender, male:female 7:3 6:4
Mean age, year (SD) 54.5 (9.5) 27.6 (2.9)
Mean FPG, mg/dL (SD) 151.0 (57.1) 83.4 (11.3)
Mean HbA1c, % (SD) 7.7 (1.1) 5.8 (0.3)
Mean creatinine, mg/dL (SD) 0.9 (0.5) 0.8 (0.2)
Mean cholesterol, mg/dL (SD) 175.5 (26.6) 204.0 (35.7)
Mean triglyceride, mg/dL (SD) 131.2 (56.7) 85.0 (26.4)
Mean AST, U/L (SD) 32.2 (13.6) 16.9 (5.7)
Mean ALT, U/L (SD) 46.6 (21.0) 29.7 (5.3)
Mean bilirubin, mg/dL (SD) 0.6 (0.3) 0.6 (0.4)
were excluded. Informed, written consent was obtained from
all subjects after explanation of the nature, purpose, and
potential risks of the study.
2.2. Plant Material and Fraction Preparation. The stems of
T. crispa were collected from Supanburi and Nakhonsitham-
marat provinces, Thailand. Plant material was identiﬁed by
Dr. Kongkathip N, Department of Chemistry, Faculty of
Science, Kasetsart University. Coarse powder of T. crispa
stem was defatted with petroleum ether (60–80◦C) and
dried material was extracted with 70% ethanol using soxhlet
apparatus at 65–70◦Cf o r7d a y s .T h ee x t r a c tw a sd r i e d
under vacuum in a rotary evaporator. Powder was used
microcrystalline cellulose at 7% of powder weight and using
dry granulation technique. Powder of 125 and 250mg T.
crispastem was prepared in form of capsule [6]. We designed
to use 250mg of T. crispa dry powder capsule because in
previous study, 250mg twice a day T. crispa can reduce
fastingbloodglucosesigniﬁcantlyfrombaselineinmetabolic
syndrome patients [7].
2.3. Methods. After the screening visit, all subjects adhered
to an alcohol-free, high-carbohydrate diet (>150g/d) and
discontinued all oral hypoglycemic agents at least 72 hours
before the study. Exercise was discontinued 24 hours before
and fasting was instituted 12 hours till the morning of the
study. The study was performed in three visits, 1 to 2 weeks
apart. The doses at each visit were as follows: 75g of glucose
at ﬁrst visit; 75g of glucose and 125mg of T. crispa dry
powder capsule at second visit; 75g of glucose and 250mg
of T. crispa dry powder capsule at third visit. Venous blood
wasdrawnandtheningestionof75gglucosewithorwithout
ingestion of 125 or 250mg of T. crispa. Additional venous
bloodsamplesweredrawnat30,60,90,120,and180minutes
afteringestion.Serumglucosewasobtainedbyanautomated
glucose oxidase method and serum insulin was measured
by radioimmunoassay kit. All participants were examined
and blood was taken for complete blood count, liver enzyme
proﬁle, and renal function at entry and end of the study.
2.4. Statistical Analyses. Areas under the curve (AUC) for
increase in serum glucose and serum insulin were calculated
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Figure 1: Mean serum glucose level at timed intervals during
glucose tolerance test for 10 diabetic and 10 healthy participants.
Mean serum glucose levels in mg/dL without (o) and with 125 (•)
and 250mg (×) ingestion of Tinospora crispa diabetic participants,
and without () and with 125 () and 250mg (∗) ingestion of
Tinospora crispa in healthy participants.
by trapezoidal rule, and means were tested for signiﬁcance
by paired t-test. Mean glucose and insulin blood levels of all
subjects were calculated for each time point. P<0.05 was
considered statistically signiﬁcant.
3. Results
All of the 20 participants who had enrolled completed the
study. At the dosage used there were no adverse eﬀects
reported by our subjects. During the treatment period no
elevationsinserumtransaminaseweredetected.Thebaseline
characteristics of the participants are shown in Table 1.
3.1. Glucose Levels with and without Ingestion of Tinospora
crispa. Table 2 shows incremental serum glucose AUC (time
0 to 180min) over the baseline in mgmin/mL for 75g
glucose ingestion with and without 125 or 250mg of T.
crispa for each participant. The mean serum glucose AUC in
both diabetic and healthy participants was not signiﬁcantly
diﬀerent between with and without T. crispa. In diabetic
participantsthemeanserumglucoseAUCwereslightlylesser
when 250mg of T. crispa was ingested, but not reaching
statistical signiﬁcance (478 and 444mgmin/mL, resp., P =
0.57). The mean glucose levels at each time interval showed
small diﬀerences with T. crispa ingestion (Figure 1).Journal of Biomedicine and Biotechnology 3
Table 2: Mean of 3h total area under the curve (AUC) glucose and 3-h total AUC insulin for 75g oral glucose tolerance test performed with
and without 125 or 250mg of Tinospora crispa.
3h total AUC for glucose (mg min/mL) 3h total AUC insulin (mIU min/mL)
Without T.
crispa
125mg T.
crispa 250mg T. crispa Without T.
crispa
125mg T.
crispa
250mg T.
crispa
DM 478 ± 135 475 ± 102 444 ± 117 61 ± 56 50 ± 37 39 ± 21
Healthy 165 ± 25 171 ± 38 171 ± 30 73 ± 55 85 ± 34 58 ± 16
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Figure 2: Mean serum insulin level at timed intervals during
glucose tolerance test for 10 diabetic and 10 healthy participants.
Mean serum insulin levels in µU/mL without (o) and with 125
(•) and 250mg (×) ingestion of Tinospora crispa in diabetic
participants, and without () and with 125 () and 250mg (∗)
ingestion of Tinospora crispa in healthy participants.
3.2. Insulin Levels with and without Ingestion of Tinospora
crispa. Table 2 shows incremental insulin in µUmin/mL
AUC (time 0 to 180min, 75g glucose tolerance tests without
and with 125 or 250mg of T. crispa) for each participant.
Mean insulin AUC (Table 2) and mean levels at each time
interval (Figure 2) in both diabetic and healthy participants
varied, little with T. crispa ingestion.
4. Discussion
This study was unable to demonstrate the eﬃcacy of T. crispa
water extract to dry powder capsule for changes in areas
under the serum glucose and insulin curves in healthy or
diabetic subjects.
This result was inconsistent with other studies in animal
model and metabolic syndrome subjects, Noor et al. [8]
showed T. crispa aqueous extract to the drinking water for
one week. Fasting blood glucose levels were signiﬁcantly
lower and serum insulin levels were signiﬁcantly higher
in treated diabetic rats (10.4 ± 1.0 mmol/l and 12.8 ±
1.1µU/mL, resp.) compared to untreated diabetic controls
(17.4 ± 1.7 mmol/l and 8.0 ± 0.7µU/mL, resp.). Kongkathip
et al. [9] found that the water extract of T. crispa caused
a 13.9–15.6% reduction of serum glucose levels in normal
rats after 120-minute oral feeding while 70% ethanol extract
decreased serum glucose levels by 8.9–13.0% after 120
minute. Acute toxicity testing showed that LD50 values of
water extracts are about 20–24g/kg. It was suggested that
the water extract of T. crispa is highly safe. Sriyapai et al.
[7] presented metabolic syndrome patients who received
250mg twicea dayT. crispa dry powder capsulefor 2 months
can reduce fasting blood glucose signiﬁcantly from baseline
(6.29 ± 10.47mg/dL, P<0.01).
on the other hand, Sangsuwan et al. [5] showed that
T. crispa had no eﬃcacy for therapy in patients with type
2 DM who did not respond to oral hypoglycemic drugs
since there were no signiﬁcant changes in fasting serum
glucose between those collected at baseline and during the
study period in either group (250 and 245mg/dL, resp.) or
glycosylated hemoglobin (10.3 and 11.2%, resp.). Our study
demonstratedthatT. crispa cannotsigniﬁcantlyreducemean
serum glucose AUC in diabetic patient but can show a trend
to reduce mean glucose AUC 478 to 444mg mL/min. 250mg
of T. crispa may not be adequate dosage to reduce serum
glucose and stimulate insulin and another reason is that it
may not last long enough to show the eﬀect of treatment.
Therefore,weneedfurtherinvestigationaboutadequatedose
of T. crispa to reduce serum glucose and stimulate insulin
secretion in type 2 diabetic patients.
5. Conclusion
The results suggest that Tinospora crispa ingestion cannot
aﬀect serum glucose and insulin levels in healthy subjects or
patients with type 2 diabetes mellitus.
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